Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents

Drugs

Volumn 73, Issue 6, 2013, Pages 517-532

  Berge, Eamon M ^a   Doebele, Robert C ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; VINBLASTINE;

ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG ERUPTION; DRUG RESPONSE; FATIGUE; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84878308675     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0032-4     Document Type: Review

References (66)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Altekruse S, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda: National Cancer Institute; 2012. http://seer.cancer.gov/csr/1975-2009-pops09/.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
4. JH Schiller D Harrington CP Belani C Langer A Sandler J Krook, et al. 2002 Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2 92 98 11784875 10.1056/NEJMoa011954 1:CAS:528:DC%2BD38Xkt1OlsQ%3D%3D
5. CG Azzoli S Baker Jr S Temin W Pao T Aliff J Brahmer, et al. 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer J Clin Oncol 27 36 6251 6266 19917871 10.1200/JCO.2009.23.5622 1:CAS:528:DC%2BC3cXht1agsbs%3D
6. G D'Addario E Felip 2009 Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 Suppl 4 68 70 19454467
7. Azzoli CG, Temin S, Giaccone G. 2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract. 2012;8(1):63-6.
8. TS Mok YL Wu CJ Yu C Zhou YM Chen L Zhang, et al. 2009 Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer J Clin Oncol 27 30 5080 5087 19738125 10.1200/JCO.2008.21.5541 1:CAS:528:DC%2BD1MXhsVCrsrrI
9. R Rosell E Carcereny R Gervais A Vergnenegre B Massuti E Felip, et al. 2012 Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 3 239 246 22285168 10.1016/S1470-2045(11)70393-X 1:CAS:528:DC%2BC38XjsVCgsbk%3D
10. EL Kwak YJ Bang DR Camidge AT Shaw B Solomon RG Maki, et al. 2010 Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 18 1693 1703 20979469 10.1056/NEJMoa1006448 1:CAS:528:DC%2BC3cXhtlKitL%2FO
11. TA Hensing MJ Schell JH Lee MA Socinski 2005 Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer Lung Cancer. 47 2 253 259 15639724 10.1016/j.lungcan.2004.07.040
12. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 24 2542 2550 17167137 10.1056/NEJMoa061884 1:CAS:528: DC%2BD28XhtlWqsbzI
13. R Pirker JR Pereira A Szczesna J von Pawel M Krzakowski R Ramlau, et al. 2009 Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 9674 1525 1531 19410716 10.1016/S0140-6736(09)60569-9 1:CAS:528:DC%2BD1MXltlaqurs%3D
14. GV Scagliotti P Parikh J von Pawel B Biesma J Vansteenkiste C Manegold, et al. 2008 Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 21 3543 3551 18506025 10.1200/JCO.2007.15.0375 1:CAS:528:DC%2BD1cXpvVWmtLg%3D
15. IE Smith ME O'Brien DC Talbot MC Nicolson JL Mansi TF Hickish, et al. 2001 Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin J Clin Oncol 19 5 1336 1343 11230476 1:CAS:528:DC%2BD3MXit1ert7k%3D
16. C von Plessen B Bergman O Andresen RM Bremnes S Sundstrom M Gilleryd, et al. 2006 Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer Br J Cancer 95 8 966 973 10.1038/sj.bjc.6603383
17. JO Park SW Kim JS Ahn C Suh JS Lee JS Jang, et al. 2007 Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer J Clin Oncol 25 33 5233 5239 18024869 10.1200/JCO.2007.10.8134 1:CAS:528: DC%2BD2sXhsVKnsbzJ
18. MA Socinski MJ Schell A Peterman K Bakri S Yates R Gitten, et al. 2002 Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer J Clin Oncol 20 5 1335 1343 11870177 10.1200/JCO.20.5.1335 1:CAS:528:DC%2BD38XisVWmu7w%3D
19. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii56-64.
20. T Brodowicz M Krzakowski M Zwitter V Tzekova R Ramlau N Ghilezan, et al. 2006 Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial Lung Cancer 52 2 155 163 16569462 10.1016/j.lungcan.2006.01.006
21. Belani CP, Waterhouse DM, Ghazal H, Ramalingam SS, Bordoni R, Greenberg R, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstr. 2010;28(15 suppl):7506.
22. M Perol C Chouaid D Perol F Barlesi R Gervais V Westeel, et al. 2012 Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 30 28 3516 3524 22949150 10.1200/JCO.2011.39.9782 1:CAS:528:DC%2BC38XhslSksrfF
23. CP Belani J Barstis MC Perry RV La Rocca SR Nattam D Rinaldi, et al. 2003 Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation J Clin Oncol 21 15 2933 2939 12885812 10.1200/JCO.2003.02.563 1:CAS:528:DC%2BD2cXpsVKjt7g%3D
24. CP Belani S Ramalingam MC Perry RV LaRocca D Rinaldi PS Gable, et al. 2008 Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer J Clin Oncol 26 3 468 473 18202422 10.1200/JCO.2007.13.1912 1:CAS:528:DC%2BD1cXitVGnurc%3D
25. Gronberg BH, Bremnes RM, Flotten O, Amundsen T, Brunsvig PF, Hjelde HH, et al. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(19):3217-24.
26. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009;14(3):253-63.
27. L Paz-Ares F de Marinis M Dediu M Thomas JL Pujol P Bidoli, et al. 2012 Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Lancet Oncol. 13 3 247 255 22341744 10.1016/S1470-2045(12)70063-3 1:CAS:528:DC%2BC38XjsVCgsbY%3D
28. Paz-Ares L, De Marinis F, Dediu M, Thomas M, Pujol J-L, Bidoli P, et al. PARAMOUNT: final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). ASCO Meeting Abstr. 2012;30(15 suppl):LBA7507.
29. DH Johnson L Fehrenbacher WF Novotny RS Herbst JJ Nemunaitis DM Jablons, et al. 2004 Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 11 2184 2191 15169807 10.1200/JCO.2004.11.022 1:CAS:528:DC%2BD2cXpsVWltrg%3D
30. SS Ramalingam SE Dahlberg CJ Langer R Gray CP Belani JR Brahmer, et al. 2008 Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599 J Clin Oncol 26 1 60 65 18165641 10.1200/JCO.2007.13.1144 1:CAS:528:DC%2BD1cXhsVCrsLk%3D
31. SE Dahlberg AB Sandler JR Brahmer JH Schiller DH Johnson 2010 Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 J Clin Oncol 28 6 949 954 20085937 10.1200/JCO.2009.25. 4482 1:CAS:528:DC%2BC3cXktF2ltr8%3D
32. AB Sandler JH Schiller R Gray I Dimery J Brahmer M Samant, et al. 2009 Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab J Clin Oncol 27 9 1405 1412 19224857 10.1200/JCO.2008.16.2412 1:CAS:528:DC%2BD1MXksF2hsro%3D
33. M Reck J von Pawel P Zatloukal R Ramlau V Gorbounova V Hirsh, et al. 2009 Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 27 8 1227 1234 19188680 10.1200/JCO.2007.14.5466 1:CAS:528:DC%2BD1MXktFKhsL0%3D
34. JD Patel TA Hensing A Rademaker EM Hart MG Blum DT Milton, et al. 2009 Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer J Clin Oncol 27 20 3284 3289 19433684 10.1200/JCO.2008.20.8181 1:CAS:528:DC%2BD1MXpvFejtrY%3D
35. Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Hermann RC, et al. A randomized, open-label, phase III, superiority study of pemetrexed (Pem) + carboplatin (Cb) + bevacizumab (Bev) followed by maintenance Pem + Bev versus paclitaxel (Pac) + Cb + Bev followed by maintenance Bev in patients with stage IIIB or IV non-squamous non-small cell lung cancer (NS-NSCLC). Paper presented at: 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology; 2012 Sep 6-8; Chicago, IL, USA; 2012.
36. R Pirker JR Pereira J von Pawel M Krzakowski R Ramlau K Park, et al. 2012 EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Lancet Oncol. 13 1 33 42 22056021 10.1016/S1470-2045(11)70318-7 1:CAS:528:DC%2BC38XkslSmtA%3D%3D
37. KJ O'Byrne U Gatzemeier I Bondarenko C Barrios C Eschbach UM Martens, et al. 2011 Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study Lancet Oncol. 12 8 795 805 21782507 10.1016/S1470-2045(11)70189-9
38. TJ Lynch T Patel L Dreisbach M McCleod WJ Heim RC Hermann, et al. 2010 Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099 J Clin Oncol 28 6 911 917 20100966 10.1200/JCO.2009.21.9618 1:CAS:528:DC%2BC3cXktF2lsbk%3D
39. G Giaccone RS Herbst C Manegold G Scagliotti R Rosell V Miller, et al. 2004 Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 5 777 784 14990632 10.1200/JCO.2004.08.001 1:CAS:528:DC%2BD2cXpsVKjur4%3D
40. RS Herbst G Giaccone JH Schiller RB Natale V Miller C Manegold, et al. 2004 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 5 785 794 14990633 10.1200/JCO.2004.07.215 1:CAS:528:DC%2BD2cXpsVKjur0%3D
41. U Gatzemeier A Pluzanska A Szczesna E Kaukel J Roubec F De Rosa, et al. 2007 Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 12 1545 1552 17442998 10.1200/JCO.2005.05.1474 1:CAS:528:DC%2BD2sXlsVynur4%3D
42. RS Herbst D Prager R Hermann L Fehrenbacher BE Johnson A Sandler, et al. 2005 TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 25 5892 5899 16043829 10.1200/JCO.2005.02.840 1:CAS:528:DC%2BD2MXhtVKgtbzN
43. V Westeel E Quoix D Moro-Sibilot M Mercier JL Breton D Debieuvre, et al. 2005 Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer J Natl Cancer Inst 97 7 499 506 15812075 10.1093/jnci/dji096 1:CAS:528:DC%2BD2MXjtFalt7g%3D
44. PM Fidias SR Dakhil AP Lyss DM Loesch DM Waterhouse JL Bromund, et al. 2009 Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer J Clin Oncol 27 4 591 598 19075278 10.1200/JCO.2008.17.1405 1:CAS:528:DC%2BD1MXivFyju74%3D
45. T Ciuleanu T Brodowicz C Zielinski JH Kim M Krzakowski E Laack, et al. 2009 Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 9699 1432 1440 19767093 10.1016/S0140-6736(09)61497-5 1:CAS:528:DC%2BD1MXhtlSru7jL
46. N Hanna FA Shepherd FV Fossella JR Pereira F De Marinis J von Pawel, et al. 2004 Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 9 1589 1597 15117980 10.1200/JCO.2004.08.163 1:CAS:528: DC%2BD2cXpsVWmurk%3D
47. F Cappuzzo T Ciuleanu L Stelmakh S Cicenas A Szczesna E Juhasz, et al. 2010 Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol. 11 6 521 529 20493771 10.1016/S1470-2045(10)70112-1 1:CAS:528:DC%2BC3cXntVCksb0%3D
48. M Fukuoka YL Wu S Thongprasert P Sunpaweravong SS Leong V Sriuranpong, et al. 2011 Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 21 2866 2874 21670455 10.1200/JCO.2010.33.4235 1:CAS:528:DC%2BC3MXhtVOqsLnO
49. C Zhou YL Wu G Chen J Feng XQ Liu C Wang, et al. 2011 Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol. 12 8 735 742 21783417 10.1016/S1470-2045(11)70184-X 1:CAS:528:DC%2BC3MXpslKhsbY%3D
50. Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a West Japan Thoracic Oncology Group trial (WJTOG0203). J Clin Oncol. 2010;28(5):753-60.
51. L Zhang S Ma X Song B Han Y Cheng C Huang, et al. 2012 Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial Lancet Oncol. 13 5 466 475 22512843 10.1016/S1470-2045(12)70117-1 1:CAS:528:DC%2BC38Xmslyhsb8%3D
52. RM Gaafar VF Surmont GV Scagliotti RJ Van Klaveren D Papamichael JJ Welch, et al. 2011 A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03) Eur J Cancer 47 15 2331 2340 21802939 10.1016/j.ejca.2011.06.045 1:CAS:528: DC%2BC3MXht1Ohs7vE
53. Miller VA, O'Connor P, Soh C, Kabbinavar F, for the ATLAS Investigators. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). ASCO Meeting Abstr. 2009;27(18S):LBA8002.
54. JP Lima LV dos Santos EC Sasse AD Sasse 2009 Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis Eur J Cancer 45 4 601 607 19111457 10.1016/j.ejca.2008.11.006
55. GF Buccheri D Ferrigno A Curcio F Vola A Rosso 1989 Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study Cancer 63 3 428 432 2536288 10.1002/1097-0142(19890201)63:3<428::AID-CNCR2820630305>3.0.CO;2-V 1:STN:280:DyaL1M7gs1SltQ%3D%3D
56. YY Soon MR Stockler LM Askie MJ Boyer 2009 Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials J Clin Oncol 27 20 3277 3283 19470938 10.1200/JCO.2008.19.4522
57. Behera M, Owonikoko TK, Chen Z, Kono SA, Khuri FR, Belani CP, et al. Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: a meta-analysis. ASCO Meeting Abstr. 2011;29(15 suppl):7553.
58. X Zhang J Zang J Xu C Bai Y Qin K Liu, et al. 2011 Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis Chest 140 1 117 126 21436247 10.1378/chest.10-2745 1:CAS:528:DC%2BC3MXhtVajtrzI
59. R Gervais JD Hainsworth N Blais B Besse J Laskin JT Hamm, et al. 2011 Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer Lung Cancer. 74 3 474 480 21680048 10.1016/j.lungcan.2011.05.004
60. De Pas T, Giovannini M, Rescigno M, Catania C, Toffalorio F, Spitaleri G, et al. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials. Crit Rev Oncol Hematol. 2012;83(3):432-43.
61. TJ Lynch I Bondarenko A Luft P Serwatowski F Barlesi R Chacko, et al. 2012 Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study J Clin Oncol 30 17 2046 2054 22547592 10.1200/JCO.2011.38.4032 1:CAS:528:DC%2BC38XhtVynsbvP
62. J Nemunaitis RO Dillman PO Schwarzenberger N Senzer C Cunningham J Cutler, et al. 2006 Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer J Clin Oncol 24 29 4721 4730 16966690 10.1200/JCO.2005.05.5335 1:CAS:528:DC%2BD28XhtFynsr3J
63. E Quoix R Ramlau V Westeel Z Papai A Madroszyk A Riviere, et al. 2011 Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial Lancet Oncol. 12 12 1125 1133 22019520 10.1016/S1470-2045(11)70259-5 1:CAS:528:DC%2BC3MXhsVSktrnI
64. Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, Catala Ferrer M, Bravo I, Mendoza del Pino M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol. 2008;26(9):1452-8.
65. SL Topalian FS Hodi JR Brahmer SN Gettinger DC Smith DF McDermott, et al. 2012 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2443 2454 22658127 10.1056/NEJMoa1200690 1:CAS:528: DC%2BC38XhtV2rs7fN
66. JR Brahmer SS Tykodi LQ Chow WJ Hwu SL Topalian P Hwu, et al. 2012 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 26 2455 2465 22658128 10.1056/NEJMoa1200694 1:CAS:528:DC%2BC38XhtV2rsbnJ